Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Off-label use of prescription analgesics among hospitalized children in the United States.

Carmack M, Berde C, Monuteaux MC, Manzi S, Bourgeois FT.

Pharmacoepidemiol Drug Saf. 2020 Feb 26. doi: 10.1002/pds.4978. [Epub ahead of print]

PMID:
32102118
2.

Trial2rev: Combining machine learning and crowd-sourcing to create a shared space for updating systematic reviews.

Martin P, Surian D, Bashir R, Bourgeois FT, Dunn AG.

JAMIA Open. 2019 Jan 11;2(1):15-22. doi: 10.1093/jamiaopen/ooy062. eCollection 2019 Apr.

3.

Improving Pediatric Academic Global Health Collaborative Research and Agenda Setting: A Mixed-Methods Study.

Rees CA, Keating EM, Dearden KA, Haq H, Robison JA, Kazembe PN, Bourgeois FT, Niescierenko M.

Am J Trop Med Hyg. 2020 Jan 13. doi: 10.4269/ajtmh.19-0555. [Epub ahead of print]

PMID:
31933470
4.

The use of opioids in low acuity pediatric trauma patients.

Foster AA, Porter JJ, Bourgeois FT, Mannix R.

PLoS One. 2019 Dec 16;14(12):e0226433. doi: 10.1371/journal.pone.0226433. eCollection 2019.

5.

Correction: The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system.

Mandl KD, Glauser T, Krantz ID, Avillach P, Bartels A, Beggs AH, Biswas S, Bourgeois FT, Corsmo J, Dauber A, Devkota B, Fleisher GR, Heath AP, Helbig I, Hirschhorn JN, Kilbourn J, Kong SW, Kornetsky S, Majzoub JA, Marsolo K, Martin LJ, Nix J, Schwarzhoff A, Stedman J, Strauss A, Sund KL, Taylor DM, White PS, Marsh E, Grimberg A, Hawkes C; Genomics Research and Innovation Network.

Genet Med. 2020 Feb;22(2):449. doi: 10.1038/s41436-019-0711-y.

6.

Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.

Rees CA, Pica N, Monuteaux MC, Bourgeois FT.

PLoS Med. 2019 Nov 21;16(11):e1002966. doi: 10.1371/journal.pmed.1002966. eCollection 2019 Nov.

7.

Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study.

Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT.

PLoS Med. 2019 Nov 5;16(11):e1002922. doi: 10.1371/journal.pmed.1002922. eCollection 2019 Nov.

8.

Pediatric Trials for Cancer Therapies with Targets Potentially Relevant to Pediatric Cancers.

Hwang TJ, Orenstein L, DuBois SG, Janeway KA, Bourgeois FT.

J Natl Cancer Inst. 2019 Oct 29. pii: djz207. doi: 10.1093/jnci/djz207. [Epub ahead of print]

PMID:
31665394
9.

The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system.

Mandl KD, Glauser T, Krantz ID, Avillach P, Bartels A, Beggs AH, Biswas S, Bourgeois FT, Corsmo J, Dauber A, Devkota B, Fleisher GR, Heath AP, Helbig I, Hirschhorn JN, Kilbourn J, Kong SW, Kornetsky S, Majzoub JA, Marsolo K, Martin LJ, Nix J, Schwarzhoff A, Stedman J, Strauss A, Sund KL, Taylor DM, White PS, Marsh E, Grimberg A, Hawkes C; Genomics Research and Innovation Network.

Genet Med. 2020 Feb;22(2):371-380. doi: 10.1038/s41436-019-0646-3. Epub 2019 Sep 4. Erratum in: Genet Med. 2019 Nov 27;:.

10.

Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation.

Bourgeois FT, Kesselheim AS.

N Engl J Med. 2019 Aug 29;381(9):875-881. doi: 10.1056/NEJMhle1901265. No abstract available.

PMID:
31461599
11.

Importance of authorship and inappropriate authorship assignment in paediatric research in low- and middle-income countries.

Rees CA, Keating EM, Dearden KA, Haq H, Robison JA, Kazembe PN, Bourgeois FT, Niescierenko M.

Trop Med Int Health. 2019 Oct;24(10):1229-1242. doi: 10.1111/tmi.13295. Epub 2019 Aug 21.

PMID:
31374140
12.

Trends in Opioid Prescribing for Adolescents and Young Adults in Ambulatory Care Settings.

Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT.

Pediatrics. 2019 Jun;143(6). pii: e20181578. doi: 10.1542/peds.2018-1578.

PMID:
31138669
13.

Cost Implications of Escalating Intravenous Acetaminophen Use in Children.

Bourgeois FT, Graham DA, Kesselheim AS, Randolph AG.

JAMA Pediatr. 2019 May 1;173(5):489-491. doi: 10.1001/jamapediatrics.2019.0101. No abstract available.

PMID:
30855654
14.

Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.

Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS.

Health Aff (Millwood). 2019 Feb;38(2):313-319. doi: 10.1377/hlthaff.2018.05330.

PMID:
30715972
15.

The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.

Dunn AG, Orenstein L, Coiera E, Mandl KD, Bourgeois FT.

J Clin Epidemiol. 2019 May;109:62-69. doi: 10.1016/j.jclinepi.2019.01.009. Epub 2019 Jan 30.

PMID:
30708175
16.

Neglected tropical diseases in children: An assessment of gaps in research prioritization.

Rees CA, Hotez PJ, Monuteaux MC, Niescierenko M, Bourgeois FT.

PLoS Negl Trop Dis. 2019 Jan 29;13(1):e0007111. doi: 10.1371/journal.pntd.0007111. eCollection 2019 Jan.

17.

Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.

Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT.

JAMA Pediatr. 2019 Jan 1;173(1):68-74. doi: 10.1001/jamapediatrics.2018.3416.

18.

Registration of published randomized trials: a systematic review and meta-analysis.

Trinquart L, Dunn AG, Bourgeois FT.

BMC Med. 2018 Oct 16;16(1):173. doi: 10.1186/s12916-018-1168-6.

19.

Availability of paediatric information in European Medicines Agency approvals.

Hwang TJ, Tomasi PA, Saint-Raymond A, Bourgeois FT.

Lancet Child Adolesc Health. 2018 May;2(5):e9. doi: 10.1016/S2352-4642(18)30101-9. Epub 2018 Apr 12. No abstract available.

PMID:
30169272
20.

Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.

Hwang TJ, Tomasi PA, Bourgeois FT.

PLoS Med. 2018 Mar 1;15(3):e1002520. doi: 10.1371/journal.pmed.1002520. eCollection 2018 Mar.

21.

A shared latent space matrix factorisation method for recommending new trial evidence for systematic review updates.

Surian D, Dunn AG, Orenstein L, Bashir R, Coiera E, Bourgeois FT.

J Biomed Inform. 2018 Mar;79:32-40. doi: 10.1016/j.jbi.2018.01.008. Epub 2018 Feb 2.

22.

Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores.

Grundy Q, Dunn AG, Bourgeois FT, Coiera E, Bero L.

JAMA. 2018 Jan 23;319(4):408-409. doi: 10.1001/jama.2017.20738. No abstract available.

23.

Unreported links between trial registrations and published articles were identified using document similarity measures in a cross-sectional analysis of ClinicalTrials.gov.

Dunn AG, Coiera E, Bourgeois FT.

J Clin Epidemiol. 2018 Mar;95:94-101. doi: 10.1016/j.jclinepi.2017.12.007. Epub 2017 Dec 19.

PMID:
29277557
24.

Development of the Precision Link Biobank at Boston Children's Hospital: Challenges and Opportunities.

Bourgeois FT, Avillach P, Kong SW, Heinz MM, Tran TA, Chakrabarty R, Bickel J, Sliz P, Borglund EM, Kornetsky S, Mandl KD.

J Pers Med. 2017 Dec 15;7(4). pii: E21. doi: 10.3390/jpm7040021. Review.

25.

Variation in Pediatric Procedural Sedations Across Children's Hospital Emergency Departments.

Miller AF, Monuteaux MC, Bourgeois FT, Fleegler EW.

Hosp Pediatr. 2018 Jan;8(1):36-43. doi: 10.1542/hpeds.2017-0045. Epub 2017 Dec 12.

26.

Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.

Hudgins JD, Bacho MA, Olsen KL, Bourgeois FT.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):161-167. doi: 10.1002/pds.4351. Epub 2017 Nov 17.

PMID:
29148107
27.

Improving the Study of New Medicines for Children With Rare Diseases.

Bourgeois FT, Hwang TJ.

JAMA Pediatr. 2018 Jan 1;172(1):7-9. doi: 10.1001/jamapediatrics.2017.4012. No abstract available.

PMID:
29131900
28.

The Evolution of Patient Diagnosis: From Art to Digital Data-Driven Science.

Mandl KD, Bourgeois FT.

JAMA. 2017 Nov 21;318(19):1859-1860. doi: 10.1001/jama.2017.15028. No abstract available.

PMID:
29075757
29.

A systematic review of the processes used to link clinical trial registrations to their published results.

Bashir R, Bourgeois FT, Dunn AG.

Syst Rev. 2017 Jul 3;6(1):123. doi: 10.1186/s13643-017-0518-3. Review.

30.

Conclusions in systematic reviews of mammography for breast cancer screening and associations with review design and author characteristics.

Raichand S, Dunn AG, Ong MS, Bourgeois FT, Coiera E, Mandl KD.

Syst Rev. 2017 May 22;6(1):105. doi: 10.1186/s13643-017-0495-6. Review.

31.

Complexity and Severity of Pediatric Patients Treated at United States Emergency Departments.

Hudgins JD, Monuteaux MC, Bourgeois FT, Nigrovic LE, Fine AM, Lee LK, Mannix R, Lipsett SC, Neuman MI.

J Pediatr. 2017 Jul;186:145-149.e1. doi: 10.1016/j.jpeds.2017.03.035. Epub 2017 Apr 7.

PMID:
28396022
32.

Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease.

Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA.

J Am Geriatr Soc. 2017 Nov;65(11):2354-2361. doi: 10.1111/jgs.14833. Epub 2017 Mar 17.

33.

The Pediatric Research Equity Act Moves Into Adolescence.

Bourgeois FT, Hwang TJ.

JAMA. 2017 Jan 17;317(3):259-260. doi: 10.1001/jama.2016.18131. No abstract available.

PMID:
28114560
34.

Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors.

Dunn AG, Zhou X, Hudgins J, Arachi D, Mandl KD, Coiera E, Bourgeois FT.

J Clin Epidemiol. 2016 Dec;80:43-49. doi: 10.1016/j.jclinepi.2016.07.010. Epub 2016 Jul 25. Review.

PMID:
27460462
35.

Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials.

Bourgeois FT, Olson KL, Tse T, Ioannidis JP, Mandl KD.

PLoS One. 2016 May 19;11(5):e0155948. doi: 10.1371/journal.pone.0155948. eCollection 2016.

36.
37.

Effect of Randomized Clinical Trial Findings on Emergency Management.

Hudgins JD, Fine AM, Bourgeois FT.

Acad Emerg Med. 2016 Jan;23(1):36-47. doi: 10.1111/acem.12840. Epub 2015 Dec 31.

38.

Measuring patient-perceived quality of care in US hospitals using Twitter.

Hawkins JB, Brownstein JS, Tuli G, Runels T, Broecker K, Nsoesie EO, McIver DJ, Rozenblum R, Wright A, Bourgeois FT, Greaves F.

BMJ Qual Saf. 2016 Jun;25(6):404-13. doi: 10.1136/bmjqs-2015-004309. Epub 2015 Oct 13.

39.

Variation and Trends in Charges for Pediatric Care in Massachusetts Emergency Departments, 2000-2011.

Monuteaux MC, Bourgeois FT, Mannix R, Samnaliev M, Stack AM.

Acad Emerg Med. 2015 Oct;22(10):1164-71. doi: 10.1111/acem.12761. Epub 2015 Sep 22.

40.

Identifying Clinical Study Types from PubMed Metadata: The Active (Machine) Learning Approach.

Dunn AG, Arachi D, Bourgeois FT.

Stud Health Technol Inform. 2015;216:867-71.

PMID:
26262175
41.

Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients.

Bourgeois FT, Olson KL, Poduri A, Mandl KD.

Paediatr Drugs. 2015 Oct;17(5):401-10. doi: 10.1007/s40272-015-0139-z.

42.

Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013.

Murthy S, Mandl KD, Bourgeois FT.

Health Res Policy Syst. 2015 Jun 5;13:28. doi: 10.1186/s12961-015-0019-6.

43.

Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors.

Zhou X, Wang Y, Tsafnat G, Coiera E, Bourgeois FT, Dunn AG.

J Clin Epidemiol. 2015 Jan;68(1):87-93. doi: 10.1016/j.jclinepi.2014.09.014. Epub 2014 Oct 22.

PMID:
25450452
44.

Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews.

Dunn AG, Arachi D, Hudgins J, Tsafnat G, Coiera E, Bourgeois FT.

Ann Intern Med. 2014 Oct 7;161(7):513-8. doi: 10.7326/M14-0933.

PMID:
25285542
45.

Variation in emergency department admission rates in US children's hospitals.

Bourgeois FT, Monuteaux MC, Stack AM, Neuman MI.

Pediatrics. 2014 Sep;134(3):539-45. doi: 10.1542/peds.2014-1278. Epub 2014 Aug 11.

46.

New regulatory paradigms for innovative drugs to treat pediatric diseases.

Hwang TJ, Bourgeois FT.

JAMA Pediatr. 2014 Oct;168(10):879-80. doi: 10.1001/jamapediatrics.2014.904. No abstract available.

47.

Premarket safety and efficacy studies for ADHD medications in children.

Bourgeois FT, Kim JM, Mandl KD.

PLoS One. 2014 Jul 9;9(7):e102249. doi: 10.1371/journal.pone.0102249. eCollection 2014.

48.

Drug safety in the digital age.

Hwang TJ, Bourgeois FT, Seeger JD.

N Engl J Med. 2014 Jun 26;370(26):2460-2. doi: 10.1056/NEJMp1401767. No abstract available.

49.

Postmarketing trials and pediatric device approvals.

Hwang TJ, Kesselheim AS, Bourgeois FT.

Pediatrics. 2014 May;133(5):e1197-202. doi: 10.1542/peds.2013-3348. Epub 2014 Apr 14.

50.

The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children.

Dunn AG, Mandl KD, Coiera E, Bourgeois FT.

PLoS One. 2013 Dec 23;8(12):e84951. doi: 10.1371/journal.pone.0084951. eCollection 2013.

Supplemental Content

Loading ...
Support Center